WT1 Peptid Vaccination in Carcinomas

Phase II Study of WT1 126-134 Peptide Vaccination in Combination With Adjuvants GM-CSF and KLH in Carcinomas

Status

UNKNOWN

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00153608

Enrollment

Registered

2005-09-12

Start date

2004-04-30

Completion date

Unknown

Last updated

2006-02-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

WT1 Expressing Carcinoma

Brief summary

In this trial HLA-A2+ patients with WT1 expressing carcinomas are vaccinated with a peptide from the leukemia associated antigen WT1 together with immunological adjuvants KLH as T-helper protein and GM-CSF

Interventions

BIOLOGICALWT1 126-134 peptide

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Metastatic cancer, no standard treatment option * Resected cancer with minimal residual disease, no standard treatment option * WT-1 expression * HLA-A2

Exclusion criteria

* Concurrent chemotherapy

Design outcomes

Primary

Measure	Time frame
Clinical efficacy	—

Secondary

Measure	Time frame
Immune response	—
Safety	—

Countries

Germany

Contacts

Primary ContactCarmen Scheibenbogen, MD

carmen.scheibenbogen@charite.de+49-30-8445-4576

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026